Corporate information
Official name
Aderis Pharmaceuticals Incorporated
Registration country
Company type
Novel small molecule, receptor-specific therapeutics company for the treatment of central nervous system, cardiovascular and renal diseases.Funding rounds
Series D USD 45,000,000
USD 45,000,000 ( )
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
|
Paladin Capital Group | Private equity firm | Initial investment. Led the round. | |
|
China Development Industrial Bank (CDIB) | Private development financial institution in Taiwan. | Initial investment. | |
|
International Biotechnology Trust PLC | Initial investment. | ||
![[current-page:title] logo](/sites/default/files/styles/icon/public/default_images/_no-logo.png?itok=AH4pbDYM){kind=icon}
|
MDS Capital Corp | Initial investment. | ||
|
|
NeoMed Management AS | Initial investment. | ||
|
|
Perseus-Soros BioPharmaceutical Fund LP | Initial investment. | ||
|
Sanderling Ventures | Initial investment. | ||
|
|
Schroder Ventures KK | Initial investment. | ||
|
|
Singapore Bio-Innovations | Initial investment. | ||
|
Temasek Holdings (Pte) Ltd | Singapore's sovereign wealth fund. | Initial investment. |
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
|
Lumira Capital Investment Management Inc (Lumira Ventures) | Canadian healthcare and life sciences venture capital firm. | Initial investment. |
Investment activity status
Active investor